Disease relevance of Tribromodeuteriomethane

• Of the 16 contaminants tested, only bromoform produced a pulmonary adenoma response that was significantly greater than the pulmonary adenoma response of vehicle-treated control mice [1].
• The ammonia-oxidizing bacterium Nitrosomonas europaea (ATCC 19718) was shown to degrade low concentrations (50 to 800 mug/liter) of the four trihalomethanes (trichloromethane [TCM], or chloroform; bromodichloromethane [BDCM]; dibromochloromethane [DBCM]; and tribromomethane [TBM], or bromoform) commonly found in treated drinking water [2].
• Radical adduct is only detectable in bile from bromoform-treated rats after the production of hypoxia [3].
• The present work was conducted to study the effect of prior dietary exposure to CD on toxicity of bromoform [4].
• In the Ames-fluctuation test, only bromoform showed mutagenic activity on Salmonella typhimurium strain TA100 [5].

High impact information on Tribromodeuteriomethane

• The amount of TBARS released from liver slices incubated with bromotrichloromethane, carbon tetrabromide, dichloromethane, bromobenzene, chloroform, bromoform, benzyl chloride, bromochloromethane, and carbon tetrabromide correlated with the lethality of these compounds as evaluated by their oral LD50 in rats [6].
• In this paper we describe the properties of bromoform acting as a general anesthetic (in Rana temporaria tadpoles) and as an inhibitor of the firefly luciferase enzyme at high and low ATP concentrations [7].
• The mono- and dibromoheptanones can be utilized as precursors for the enzymatic formation of tribromoheptanone, but the final hydrolysis of the tribromoheptanone to bromoform appears to be a nonenzymatic reaction with the P. capitatus extracts [8].
• Bromoform is a halogenated alkane that exhibits anesthetic properties and has been shown by X-ray crystallography to bind to model anesthetic targets [9].
• In the present study, we have determined the genotoxicity of one of the brominated THMs, bromoform (BF), by measuring its ability to induce sister chromatid exchanges (SCEs) in whole-blood (WB) cultures of human peripheral blood lymphocytes from GSTT1-1+ and GSTT1-1- donors [10].

Biological context of Tribromodeuteriomethane

• Field bean protease inhibitor mitigates the sister-chromatid exchanges induced by bromoform and depresses the spontaneous sister-chromatid exchange frequency of human lymphocytes in vitro [11].
• The biotransformation of bromoform to CO was characterized with respect to time course, microsomal protein concentration, pH and temperature [12].
• Among the four THMs, bromoform and DBCM kinetics appeared to be more sensitive to the mixture effect and to exert the greatest impact on the kinetics of the second THM present in the mixture [13].
• 2. The THMs, which include chloroform, bromodichloromethane, dibromochloromethane, and bromoform, are reaction by-products of water disinfection by chlorination [14].
• Chlorodibromomethane and bromodichloromethane have previously been tested in the mouse micronucleus test and did not induce chromosome damage, but results from two previous micronucleus tests on bromoform are somewhat contradictory [15].

Anatomical context of Tribromodeuteriomethane

• Free radical intermediates were also detected during the aerobic and anaerobic incubation of isolated hepatocytes with bromoform (CHBr3), and iodoform (CHI3) [16].
• In the present study, bromoform was tested in the mouse bone marrow micronucleus test in order to reassess the response in this system; all three compounds were evaluated using the rat liver unscheduled DNA synthesis test [15].
• Hydrophobic nonionic compounds, such as bromoform and chloroform, exhibited a high initial rejection, as a result of both hydrophobic-hydrophobic solute-membrane interactions and steric exclusion, but rejection decreased significantly after 10 hours of operation because of partitioning of solutes through the membranes [17].

Associations of Tribromodeuteriomethane with other chemical compounds

• GLC determination of PPB levels of citrate by conversion to bromoform [18].
• At least some of them (bromodichloromethane, bromoform) have been shown to be carcinogenic in laboratory animals [19].
• Analysis of the reduction kinetics showed that CTB and BF were mainly reduced through hydrogenolysis reaction, while over 76% of DBM was reduced through concerted reductive debromination to methane [20].
• In vitro studies were conducted using 0.1-0.5 ml whole blood, or an equivalent mixture of water and n-octanol exposed to varying amounts of VOCs (BF, 0.11-11.4 micromol; CB, 0.11-24.6 micromol; CF, 0.11-186.6 micromol; and EB, 0.11-20.2 micromol) in sealed glass vials [21].

Gene context of Tribromodeuteriomethane

• Induction of sister chromatid exchanges in human peripheral blood lymphocytes by bromoform: investigation of the role of GSTT1-1 polymorphism [10].
• This vibrationally excited bromoform readily surpasses a reaction barrier 389.6 kJ/mol prior to decomposition [22].

Analytical, diagnostic and therapeutic context of Tribromodeuteriomethane

• A new solvate of griseofulvin wih bromoform was characterized by Raman spectroscopy [23].
• Bromoform or chloroform was added to the mobile phase in HPLC to compare the difference between bromine and chlorine adducted ions [24].
• To evaluate this phenomenon in humans, we have examined the genotoxicity of a brominated THM, bromoform (BF), using the Comet assay in human whole blood cultures exposed in vitro [25].

References